Core Insights - LifeVantage Corporation announced new in vitro study results for its proprietary P84 formula, demonstrating significant biological activity in cellular pathways related to gut regulation, repair, and restoration [1][2] Group 1: Study Findings - The study measured targeted gene expression and protein concentration across four gut cell types, examining 14 gut peptides and proteins that regulate gut health [1] - All 14 peptides were positively influenced, with notable increases such as GRP (gastrin-releasing peptide) showing an increase of 1,087%, TFF3 (trefoil factor 3) increasing by 116%, and VIP (vasoactive intestinal peptide) increasing by 100% [6] - The results exceeded typical biomarker changes of 20-30%, indicating a strong impact of P84 on gut health [2] Group 2: Product Development and Strategy - The next phase of research will involve mRNA sequencing analysis of the P84 blend in combination with other LifeVantage products, including Protandim Nrf2 Synergizer and MindBody GLP-1 System™ [3] - LifeVantage integrated P84 into its product portfolio following the acquisition of LoveBiome, a company focused on gut and microbiome health, in October 2025 [4] - P84 is marketed as part of the Healthy Edge Stack, aimed at enhancing consumer health through cellular activation [4] Group 3: Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can influence gene expression and health [5] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the comprehensive gut activator P84 [5]
New Study Finds LifeVantage's P84 Positively Impacts Gut Peptide Production, Activating Key Elements for Comprehensive Gut Health